Drugs / DS-1971
DS-1971
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02564861 | Sep → Dec 2015 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02473627 | May → Jul 2015 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02266940 | Nov 2014 → Jan 2015 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02261376 | Sep → Nov 2014 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02190058 | Jul → Nov 2014 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02107885 | Mar → Jul 2014 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02673866 | Feb 2016 → Jan 2017 | diabetes mellitus, neuropathy, painful | Daiichi Sankyo | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1971 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02107885 ↗ |
| Known as | CPD 6O | ChEMBL registry synonym — accepted as the source's own label CHEMBL4633566 ↗ |
| Known as | DS 1971a | “DS 1971a is supplied as a powder or crystals and will be given as an oral suspension” NCT02564861 ↗ |
| Modality | Small molecule | — CHEMBL4633566 ↗ |
| Route | Oral | “following oral administration” NCT02190058 ↗ |